News - Bayer, Johnson & Johnson

Filter

Current filters:

BayerJohnson & Johnson

Popular Filters

1 to 25 of 37 results

ACC 2014: Bayer presents new data for Xarelto and initiates new Phase III trials

ACC 2014: Bayer presents new data for Xarelto and initiates new Phase III trials

01-04-2014

German drug major Bayer presented new analyses from the pivotal ROCKET AF and EINSTEIN clinical trials…

BayerCardio-vascularJohnson & JohnsonPharmaceuticalResearchXarelto

Another FDA delay for Bayer/J&J’s Xarelto in ACS indication

Another FDA delay for Bayer/J&J’s Xarelto in ACS indication

14-02-2014

There was further negative news for Germany’s Bayer and partner US health care giant Johnson & Johnson,…

BayerCardio-vascularJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationUSAXarelto

FDA advisory panel nixes approval of J&J and Bayer’s Xarelto for wider use

FDA advisory panel nixes approval of J&J and Bayer’s Xarelto for wider use

17-01-2014

The US Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee has voted against…

BayerCardio-vascularJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationUSAXarelto

Bayer/Janssen's Xarelto poised to lead sales in VTE market: report

30-08-2013

German drug major Bayer (BAYN: DE) and Johnson & Johnson (NYSE: JNJ) subsidiary Janssen's Xarelto (rivaroxaban)…

BayerBristol-Myers SquibbCardio-vascularEliquisGlobalJanssenJohnson & JohnsonMarkets & MarketingPfizerPharmaceuticalXarelto

Setback for Janssen and Bayer's Xarelto as FDA calls for more info in stent thrombosis setting for ACS patients

01-07-2013

Janssen Research & Development, a unit of US health care giant Johnson & Johnson (NYSE: JNJ) revealed…

BayerCardio-vascularJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationXarelto

Bayer's Xarelto gains EU clearance for secondary prevention after ACS

28-05-2013

German chemical and pharma group Bayer (BAYN: DE) says that its novel oral anticoagulant Xarelto (rivaroxaban)…

BayerCardio-vascularEuropeJohnson & JohnsonPharmaceuticalRegulationXarelto

Xarelto and Eliquis set to displace current therapies in DVT/PE

28-03-2013

Clinical data and the opinions of interviewed thought leaders indicate that there is little to distinguish…

BayerBristol-Myers SquibbCardio-vascularEliquisEuropeJohnson & JohnsonMarkets & MarketingNorth AmericaPfizerPharmaceuticalXarelto

Bayer and J&J initiate new trials to expand use of Xarelto

08-03-2013

German drug major Bayer (BAYN: DE) and partner Janssen, a subsidiary of US health care giant Johnson…

BayerCardio-vascularJanssenJohnson & JohnsonPharmaceuticalResearchXarelto

Bayer and Janssen link with Portola for Xarelto antidote

06-02-2013

Germany's Bayer (BAYN: DE) and Janssen Pharmaceuticals, a part of US health care giant Johnson & Johnson…

BayerCardio-vascularJanssenJohnson & JohnsonPharmaceuticalPortola PharmaceuticalsPRT4445Research

New drug options for advanced prostate cancer

13-12-2012

Prostate cancer is becoming increasingly common due to globally growing numbers of elderly men, and scientists…

AlpharadinAstellas PharmaBayerGlobalJohnson & JohnsonMarkets & MarketingMedivationOncologyPharmaceuticalXtandiZytiga

Big Pharma doing more for access to medicine in developing countries than two years ago

28-11-2012

The latest Access to Medicine Index, which ranks the top 20 pharmaceutical companies on their efforts…

AstraZenecaBayerGlaxoSmithKlineGlobalHealthcareJohnson & JohnsonMerck KGaAPharmaceuticalPricingResearch

Atrial fibrillation drug market will grow from $2.7 billion in 2011 to $9.2 billion in 2021

13-11-2012

The atrial fibrillation drug market will experience dramatic growth over the next decade, increasing…

BayerBristol-Myers SquibbCardio-vascularEliquisGlobalJohnson & JohnsonMarkets & MarketingPfizerPharmaceuticalXarelto

FDA expands Bayer/Janssen's Xarelto use to treat, reduce recurrence of blood clots

05-11-2012

The US Food and Drug Administration (FDA) late Friday approved German drug major Bayer's (BAYN: DE) oral…

BayerBiotechnologyCardio-vascularJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationXarelto

Janssen responds to FDA's Xarelto CRL; resubmits sNDA

10-09-2012

Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Research & Development, German drug major Bayer's (BAYN:…

BayerCardio-vascularJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationXarelto

Bayer and J&J's Xarelto aids survival after heart attack

27-08-2012

A major subgroup analysis from the ATLAS ACS 2-TIMI 51 study of 7,817 patients with acute coronary syndrome…

BayerCardio-vascularJohnson & JohnsonPharmaceuticalResearchXarelto

US priority review for two Xarelto sNDAs; one dropped

10-07-2012

The US Food and Drug Administration has assigned a priority review designation to the supplemental New…

BayerCardio-vascularJanssenJohnson & JohnsonNorth AmericaPharmaceuticalRegulationXarelto

Disappointing FDA views for Bayer's Xarelto and Pozen ulcer drug

22-06-2012

Bayer HealthCare, a unit of Germany's Bayer (BAYN: DE) says that it has received a complete response…

BayerCardio-vascularGastro-intestinalsJohnson & JohnsonNorth AmericaPA32540PharmaceuticalPozenRegulationXarelto

US FDA advisory panel votes against added indication for Bayer's Xarelto

24-05-2012

Despite relatively positive briefing papers earlier this week (The Pharma Letter May 22), the US Food…

BayerCardio-vascularJohnson & JohnsonNorth AmericaPharmaceuticalRegulationXarelto

FDA staffers basically back Xarelto for ACS but identify missing data in study

22-05-2012

The US Food and Drug Administration advisory panelists due to revue Johnson & Johnson (NYSE: JNJ) and…

BayerCardio-vascularJohnson & JohnsonNorth AmericaPharmaceuticalRegulationXarelto

1 to 25 of 37 results

Back to top